Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

31.540
-0.640-1.99%
Volume:9.96M
Turnover:314.16M
Market Cap:191.26B
PE:28.92
High:32.860
Open:32.380
Low:31.180
Close:32.180
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.25
T/O Rate:0.16%
Dividend:0.50
Dividend Rate:1.57%
EPS(LYR):1.091
ROE:19.40%
ROA:9.08%
PB:4.32
PE(LYR):28.92
PS:10.26

Loading ...

Hansoh Pharmaceutical Group Stock Sheds 2.0% in Hong Kong

Dow Jones
·
Oct 09

Hansoh Pharmaceutical Group Stock Falls 5.1% in Hong Kong

Dow Jones
·
Oct 08

Movement Alert|HANSOH PHARMA Falls 3.01% in Regular Trading, Major Shareholder Affiliates Reduced Stakes and EU Marketing Revocation for Aumolertinib

Market Focus
·
Oct 08

Does China Cancer Drug Filing Change The Bull Case For Hansoh Pharmaceutical Group (SEHK:3692)?

Simply Wall St.
·
Oct 07

Hansoh Pharmaceutical Group Stock Rises 1.7% in Hong Kong

Dow Jones
·
Oct 06

Cantrust (Far East) Limited Cuts Stake in Hansoh Pharma (03692) by 124,000 Shares at About HK$33.96 Each

Stock News
·
Oct 05

HANSOH PHARMA: JQC International Limited Disposes of Shares, Long Position Falls to 15.16%

HK Disclosure
·
Oct 05

HANSOH PHARMA: Junda Cen Disposes of Shares, Long Position Falls to 15.16%

HK Disclosure
·
Oct 05

HANSOH PHARMA: APEX MEDICAL COMPANY LTD. Disposes of Shares, Long Position Falls to 15.16%

HK Disclosure
·
Oct 05

HANSOH PHARMA: JQC Holding Limited Disposes of Shares, Long Position Falls to 15.16%

HK Disclosure
·
Oct 05

Hansoh Pharma Says Phase III Lighten Trial Shows 19.3% Weight Loss at Week 48 with Olatorepatide 15 Mg

Reuters
·
Oct 05

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Hansoh Pharmaceutical Group Stock Slips 3.3% in Hong Kong

Dow Jones
·
Oct 02

Hansoh Pharmaceutical Group (SEHK:3692) Could Be 30% Undervalued On Late Stage Drug Progress

Simply Wall St.
·
Oct 02

Movement Alert|HANSOH PHARMA Falls 3.97% in Regular Trading, EU Revocation of Aumolertinib Approval Continues to Weigh on Sentiment

Market Focus
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Hansoh Pharmaceutical Group Stock Rises 5.3% in Hong Kong

Dow Jones
·
Sep 30

Movement Alert|HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally

Market Focus
·
Sep 30

EU Withdrawal of Aumseqa Exposes Hansoh Pharma's Compliance Gaps and Global Ambitions

Deep News
·
Sep 29

JPMorgan: Merck/Daiichi Sankyo Withdrawal of B7-H3 ADC Filing Is a Positive for Hansoh Pharma/GSK's Ris-Rez

Stock News
·
Sep 28